Reaction

Duodenal Ulcer Haemorrhage reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,836 reports · 104 co-occurring drugs

As of the last recalculation, Duodenal Ulcer Haemorrhage appears in 2,836 FAERS reports alongside 104 co-occurring drug terms. The strongest observed disproportionality signal is RIVAROXABAN (PRR 18.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Rivaroxaban	444	18.4	18.4
Cimetidine	18	13.8	13.8
Clopidogrel Bisulfate	166	12.6	12.6
Quinine	13	11.2	11.2
Naproxen	108	10.5	10.5
Clopidogrel	250	10.1	10.1
Fondaparinux Sodium	11	10.0	10.0
Sucralfate Oral	19	9.9	9.9
Sucralfate Oral Suspension	19	9.8	9.8
Diclofenac	101	8.9	8.9
Ibuprofen Capsule	221	8.7	8.7
Ibuprofen Tablet, Film Coated	221	8.7	8.7
Ibupfrofen	221	8.7	8.7
Ibuprofen Tablets Usp, 200Mg	221	8.7	8.7
Ibuprofen Oral	221	8.7	8.7
Ibuprofen Capsules 200 Mg	221	8.7	8.7
Ibuprofen 200 Mg	221	8.7	8.7
Ibuprofen 200Mg	221	8.7	8.7
Enoxaparin Sodium	66	8.6	8.6
Isosorbide Mononitrate	24	8.6	8.6
Brinzolamide	10	8.5	8.5
Bisoprolol Fumarate	149	8.4	8.4
Naproxen Sodium	151	8.1	8.1
Heparin Sodium	15	8.0	8.0
Diclofenac Sodium	153	7.8	7.8
Indomethacin	14	7.8	7.8
Dalteparin Sodium	11	7.7	7.7
Lactulose	39	7.6	7.6
Apixaban	67	7.5	7.5
Warfarin Sodium	46	7.4	7.4
Prasugrel Hydrochloride	10	7.2	7.3
Ibuprofen	245	7.2	7.2
Aspirin	443	7.0	7.0
Donepezil Hydrochloride	34	6.9	6.9
Dapagliflozin	29	6.8	6.8
Sucralfate	22	6.8	6.8
Aspirin 325 Mg	402	6.6	6.6
Aspirin 81 Mg	402	6.6	6.6
Febuxostat Tablets 40 Mg	9	6.5	6.5
Febuxostat Tablets 80 Mg	9	6.5	6.5
Nebivolol	14	6.5	6.5
Basiliximab	10	6.3	6.3
Diclofenac Sodium 1%	30	6.2	6.2
Diclofenac Sodium Topical	30	6.2	6.2
Diclofenac Sodium Topical Gel, 1%	30	6.2	6.2
Ketoprofen	11	6.2	6.2
Warfarin	103	6.1	6.1
Polatuzumab Vedotin	8	6.0	6.0
Ticagrelor	26	6.0	6.0
Naproxen Sodium Tablet, Coated	11	6.0	6.0
Naproxen Sodium, Coated Tablets	11	6.0	6.0
Naproxen Sodium 220Mg	11	6.0	6.0
Candesartan Cilexetil	21	5.9	5.9
Pemetrexed	17	5.8	5.9
Digoxin	56	5.8	5.8
Pitavastatin Calcium	8	5.8	5.8
Cetuximab	24	5.7	5.7
Enalapril Maleate	19	5.7	5.7
Lubiprostone	7	5.4	5.4
Isosorbide Dinitrate	14	5.3	5.3
Panitumumab	11	5.2	5.2
Felodipine Extended-Release Tablets	8	5.2	5.2
Felodipine	8	5.2	5.2
Atezolizumab	27	5.1	5.1
Tamsulosin Hydrochloride	14	5.1	5.1
Piperacillin Sodium And Tazobactam Sodium	13	4.9	4.9
Everolimus Tablets	11	4.8	4.8
Pemetrexed Disodium	24	4.7	4.7
Dabigatran Etexilate Mesylate	45	4.6	4.6
Eplerenone	8	4.6	4.6
Dutasteride	5	4.5	4.5
Lenvatinib	20	4.5	4.5
Naproxen Sodium Tablet	32	4.5	4.5
Deferasirox	16	4.4	4.5
Chlorthalidone	7	4.4	4.4
Dabigatran Etexilate	46	4.4	4.4
Brentuximab Vedotin	6	4.3	4.3
Nintedanib	18	4.2	4.2
Umeclidinium	5	4.1	4.1
Posaconazole Delayed-Release	6	4.0	4.0
Irinotecan Hydrochloride	7	4.0	4.0
Febuxostat	9	4.0	4.0
Bevacizumab	63	3.8	3.8
Brimonidine Tartrate	9	3.7	3.7
Encorafenib	5	3.7	3.7
Ranolazine	5	3.5	3.5
Cisplatin	37	3.5	3.5
Acetaminophen, Aspirin, And Caffeine	10	3.5	3.5
Acetaminophen, Aspirin (Nsaid) And Caffeine	8	3.5	3.5
Gefitinib	4	3.3	3.3
Fluorouracil Cream, 0.5%	33	3.2	3.2
Docetaxel Anhydrous	29	3.2	3.2
Docetaxel	29	3.2	3.2
Fluorouracil	33	3.2	3.2
Entecavir	5	3.1	3.1
Ledipasvir And Sofosbuvir	8	3.1	3.1
Tolvaptan	6	3.0	3.0
Gemcitabine Hydrochloride	21	2.9	2.9
Crizotinib	5	2.9	2.9
Darbepoetin Alfa	21	2.9	2.9
Gemcitabine	15	2.8	2.8
Sevelamer Carbonate	4	2.6	2.6
Trifluridine And Tipiracil	3	2.1	2.1
Methoxy Polyethylene Glycol-Epoetin Beta	3	2.0	2.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.